In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next-Generation Combination Therapy In Oncology

Executive Summary

Despite significant scientific advances tied to the molecular understanding of cancer, clinical advances have been more limited, largely because the complexity of most tumors defies novel single-target approaches. Clinical advances in the future will require developing rational combinations of targeted therapeutics, as well as leveraging advances in biomarkers and clinical trial design. Vetting new targets with a biomarker, pursuing them in combination trials with several targeted agents, and efficiently moving the resulting rational combination through development to regulatory approval will be the roadmap for commercial success.

Advertisement

Related Content

Biopharma In 2011: A Year Of Transition
Front-Line Of Melanoma Market Could Be Marketing Battle
What New Cancer Pathway Programs Mean For The Drug Industry
AZ and Merck: Moving Forward Cautiously

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel